Frazier Life Sciences — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
MBX BiosciencesNASDAQ: MBXNov 2022SEC filingmedium confidence
BiotechCarmel, US
Timothy Knickerbocker(Executive Officer, Director)Richard DiMarchi(Executive Officer, Director)Peter Kent Hawryluk(Executive Officer, Director)
Board seatPatrick Heron· per SEC Form D · $115.2M raise · filed Nov 2022
Aldebaran TherapeuticsFeb 2022SEC filingmedium confidence
BiotechWaltham, US
Chris Pacheco(Director)Carlos Loya(Executive Officer, Director)
Board seatLauren Mifflin· per SEC Form D · $1.2M raise · filed Mar 2022
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.